EUCTR2011-004011-24-AT进行中（未招募）1 期
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR RECURRENCE
F. Hoffman-La Roche Ltd.0 个研究点目标入组 475 人开始时间: 2012年8月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 475
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients age = 18 years
- •Patients with completely resected, histologically confirmed, Stage IIC or Stage III, cutaneous melanoma where the BRAFV600 mutation status of the current primary tumor or involved lymph node is determined to be positive using the cobas® BRAF V600 Mutation Test. Patients with Stage IIIA disease must have at least one lymph node metastasis measuring > 1 mm in diameter
- •ECOG performance status of 0 or 1
- •Life expectancy of at least 5 years
- •Adequate hematologic, liver, and renal function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 373
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 102
排除标准
- •History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted therapy, hormonal therapy or photodynamic therapy) for the treatment or prevention of melanoma, including interferon-alpha-2b and pegylated interferon-alpha-2b
- •History of radiotherapy for the treatment of melanoma
- •Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first study drug administration except for adequately treated (with curative intent) basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer. This requires that the patient pathology evaluation of the screening Papanicolaou (Pap) smear, and of any polyps resected at the screening coloscopy, is negative for invasive malignancy.
- •Known personal history of more than three (>3) adenomatous colorectal polyps or a personal history of adenomatous colorectal polyp(s) > 2 cm in size. This also applies to the screening colonoscopy for select patients.
- •History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions or recurrent lymph node involvement after resection of a primary melanoma with lymph node involvement at any time in the past
- •History or current radiographic or pathologic evidence of distant metastases
- •History of clinically significant cardiac dysfunction including serious arrhythmias requiring treatment (except for atrial fibrillation and paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months prior to randomization, and history of congenital long QT syndrome or QTc interval > 450 ms at baseline
- •Current, recent (within 28 days prior to randomization) or planned use of any investigational product outside of this study
研究者
相似试验
进行中（未招募）
1 期
A Study of Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate CancerMetastatic Castrate-Resistant Prostate CancerMedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 100000004864EUCTR2016-004429-17-DKF. Hoffmann-La Roche Ltd1,101
尚未招募
不适用
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS-N118 Other chronic tubulo-interstitial nephritis-N11Other chronic tubulo-interstitial nephritisN11N118PER-007-20F. HOFFMANN-LA ROCHE LTD.,
进行中（未招募）
1 期
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Generalized Myasthenia GravisGeneralized Myasthenia Gravis (gMG)MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-004436-21-NLF. Hoffmann-La Roche Ltd240
招募中
1 期
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with NMDAR or LGI1 mediated autoimmune EncephalitisMDAR or LGI1 mediated autoimmune EncephalitisMedDRA version: 20.0Level: PTClassification code 10072378Term: Encephalitis autoimmuneSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002395-39-NLF. Hoffmann-La Roche Ltd152
进行中（未招募）
1 期
A Study of Atezolizumab with or without Tiragolumab (Anti-TIGIT Antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have not Progressed following Definitive Concurrent Chemoradiotherapy.Esophageal squamous cell carcinomaMedDRA version: 21.0Level: LLTClassification code 10055476Term: Esophageal squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001178-31-DEF. Hoffmann-La Roche Ltd750